AUTH/2177/10/08: Allergan v Merz Pharma (Xeomin leavepiece) – misleading implied clinical advantage from “free from complexing proteins” | PMCPA Case

📊

Key facts

⌄

Case	AUTH/2177/10/08
Parties	Allergan v Merz Pharma UK Ltd
Material	Xeomin leavepiece (ref 1056/XEO/MAY/2008/SM)
Product	Xeomin (Botulinum neurotoxin type A)
Comparator mentioned	Botox (Botulinum neurotoxin type A) supplied by Allergan
Main issues	Misleading implication of special merit/clinical advantage from “free from complexing proteins” when used with horse chestnut visual; misleading antibody-related claim
Key claims/visuals	“The first Botulinum neurotoxin free from complexing proteins”; horse chestnut emerging from spiky shell; “Low foreign protein load suggests low potential for neutralising antibody formation”
Applicable Code year	2008
Breach clauses	7.2 (x2), 7.8, 7.10
Undertaking breach alleged?	Yes (taken up by the Director), but no breach of Clause 25 ruled on appeal; consequently Clauses 9.1 and 2 findings did not stand
Sanctions	Undertaking received; Additional sanctions: Not stated
Complaint received	20 October 2008
Case completed	16 February 2009
Appeal	Appeal by respondent (Merz); unsuccessful on Clauses 7.2/7.8/7.10; successful on alleged undertaking breach

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

Allergan complained about a Merz Pharma UK Ltd leavepiece for Xeomin (Botulinum neurotoxin type A) (ref 1056/XEO/MAY/2008/SM).
The leavepiece headline stated: “The first Botulinum neurotoxin free from complexing proteins”, placed above an image of a horse chestnut emerging from a spiky shell.
Allergan alleged the headline + visual implied a special merit/clinical advantage for Xeomin versus other botulinum toxins with complexing proteins, which could not be substantiated.
The leavepiece also included the claim: “Low foreign protein load suggests low potential for neutralising antibody formation”; Allergan argued this was not clinically proven and had previously been qualified elsewhere with “These observations have not been confirmed in the clinical setting”.
Because the complaint implied a possible breach of an earlier undertaking (Case AUTH/2119/4/08), the Director also asked Merz to comment in relation to Clauses 2, 9.1 and 25 (undertakings). That aspect was considered separately.
Merz argued the “free from complexing proteins” statement was factual (from the SPC) and the horse chestnut was a metaphor for the toxin being “released” from complexing proteins; Merz also argued there was merit in removal (including immunogenicity arguments), but the panels focused on what the material implied to readers.

⚖️

⌄

Breaches upheld (on appeal): Clauses 7.2 (x2), 7.8 and 7.10.
The Appeal Board held that even though the headline was true, in context (especially with the horse chestnut visual) it implied an unproven special merit/clinical advantage.
The claim about low foreign protein load and low potential for neutralising antibodies was ruled misleading because clinically the antigenic potential of Xeomin still had to be established; “suggests” did not remove the impression of proof.
No breach of undertaking (on appeal): the Appeal Board did not consider the leavepiece breached the undertaking from Case AUTH/2119/4/08; therefore the Panel’s additional findings under Clauses 25, 9.1 and 2 did not stand.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access